AI Drug Discovery Company Elix Commences Joint Research With Proprietary Screening Technology Holder SEEDSUPPLY

Tokyo–(Business Wire)–Elix, Inc. (CEO: Shinya Yuki / HQ: Tokyo, hereinafter “Elix”) and SEEDSUPPLY Inc. (CEO: Naoki Tarui / HQ: Kanagawa, hereinafter “SEEDSUPPLY”) announce the start of joint research.

SEEDSUPPLY ( proposes a rapid drug discovery process for small molecules that uses binder selection technology as a proprietary hybrid screening method. This technique can perform the binding assay of any protein or RNA; Therefore, biochemical activity measurements can provide drug discovery seeds for a variety of drug discovery targets, including challenging drug discovery targets. In addition, An integrated database built for specific drug discovery target classes for target selection; It will improve the efficiency and success rate of drug discovery processes. In addition, The database presents the potential for wider applications.

Also Read :  Final defendants in Washington, Ga., area drug trafficking conspiracy enter guilty pleas | USAO-SDGA

Elix ( is an AI drug discovery company with a mission of “Rethinking Drug Discovery”. To reduce cost and time while increasing the success rate of the drug discovery pipeline, Elix helps pharmaceutical companies; The focus is on the use of machine learning in projects aimed at universities and research institutes. Elix has developed “Elix Discovery™”, an all-in-one platform for AI drug discovery that provides everything from property prediction and molecular design models to consulting and implementation support in one package ( . In addition to currently supporting drug discovery, Elix is ​​also considering in-house drug discovery.

Also Read :  What is the Q Collar, the device NFL players are wearing around their necks

In this joint research project, SEEDSUPPLY will use Elix’s proprietary AI technology with the aim of dramatically increasing the efficiency of screening processes. Elix SEEDSUPPLY’s rich data; Its data, particularly on key drug discovery targets such as membrane proteins, will be fed into the AI’s training pipeline. Therefore, the technology will be improved. In silico Techniques to screen compounds with superior properties.

Elix and SEEDSUPPLY aim to leverage their respective strengths to reduce the cost and time of small molecule drug discovery, which has proven difficult for traditional drug discovery approaches.

Also Read :  Apple advances user security with powerful new data protections

  • Elix CEO Shinya Yuki comments

    By combining data obtained through SEEDSUPPLY’s proprietary technology and our proprietary AI models, we expect to discover even more unique technological developments. We believe this technology has great potential in cost-effective screening of very difficult targets in a short period of time and efficient search of a wide chemical space.

  • Comments from Naoki Tarui, CEO of SEEDSUPPLY

    Our company’s integrated database is of the highest quality; Because all its contents are measured in the same way. Combining this with Elix’s superior AI technology is expected to create new advancements in AI drug discovery technology.


Leave a Reply

Your email address will not be published.

Related Articles

Back to top button